Clinical Trial Update: TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating TDLN-sparing radiotherapy plus immunotherapy and chemotherapy for locally advanced esophageal cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Snippet

Sponsor: Fudan University | Conditions: Esophageal Carcinoma, Radiotherapy | Phase 3 | Status: RECRUITING